The grant includes non-qualified stock options for 7,000 shares at an exercise price of $11.76, matching the Nasdaq closing price on the date of issuance. The vesting schedule for these options begins with a 25% stake on the first anniversary, followed by monthly installments over the subsequent 36 months. Additionally, the employee received 3,500 restricted stock units, which follow a four-year vesting timeline with annual installments.

These awards were issued under the 2026 Employment Inducement Incentive Award Plan, a framework established by the board of directors in April 2026 to facilitate talent acquisition. The move complies with Nasdaq Listing Rule 5635(c)(4), which allows companies to grant equity outside of stockholder-approved plans to attract new personnel. Atrium Therapeutics, which focuses on RNA-based treatments for cardiomyopathies, currently manages a pipeline featuring candidates like ATR 1072 and ATR 1086.